ACE Inhibitors Market Research Report - Global Forecast till 2027

Global ACE Inhibitors Market: Information by Drug (Lisinopril, Ramipril, Enalapril, Benazepril, Fosinopril, Captopril, Moexipril and  others), Application (Heart Failure, Hypertension, Diabetes, Heart Attack, Chronic Kidney Disease and others), Dosage Form (Oral Tablets and Oral Solution), Distribution Channel (Retail Pharmacy, Hospital Pharmacy, E-commerce Websites and Online Drug Stores) and Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2027

ID: MRFR/HC/7159-HCR | February 2021 | Region: Global | 118 pages

Please note that the assessment period of report has been updated from 2019-2025 to 2020-2027. Cordially fill the sample form for updated data.

Market Forecast

ACE Inhibitors Market is expected to reach around USD 7682.8 Million by 2025 and is expected to register a CAGR of 3.10% between 2019 and 2025.

Market Synopsis

ACE inhibitors are a common choice of medications used to control high blood pressure. Benazepril, captopril, enalapril, cilazapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, and trandolapril are some of the ACE inhibitors used for treating hypertension. The prescribing rate of different types of ACE inhibitors varies according to the country. For instance, in New Zealand, about 60% of the people taking angiotensin-converting enzyme (ACE) inhibitors are prescribed cilazapril, whereas, in the UK and Australia, cilazapril is less frequently used.

Various major pharmaceutical companies are developing innovative products that are also contributing to the growth in the market. For instance, in January 2017, Silvergate Pharmaceuticals, Inc. launched Epaned to tackle hypertension and heart failure. It is the first ready to use Ace inhibitor in oral solution form. Moreover, increasing the risk of developing high blood pressure and cardiovascular disorders due to the changing lifestyle ensures the growth in the ACE inhibitors market.

Market Drivers

  • The growing adoption of ACE Inhibitors in the management of chronic disorders is expected to drive the market growth. In the hypertensive drugs segment, ACE Inhibitors are commonly used products after diuretics.

  • The increasing prevalence of hypertension and other cardiovascular disorders is driving the demand for ACE Inhibitors. For instance, according to data published by the Centers for Disease Control and Prevention in October 2017, the prevalence of hypertension among adults in the US was 29.0% from 2015 to 2016.

  • The rising demand for less expensive drugs to manage medical complications related to heart is expected to have a positive impact on the growth of the global ACE Inhibitors market.

  • Physical inactivity, unhealthy diet, and obesity collectively increase the risk of raised blood pressure (hypertension)

Market Restraints

  • Side effects associated with the treatment, such as the increased risk of lung cancer due to usage of ACE inhibit is likely to hamper the market growth.


By Drug

  • Lisinopril: Lisinopril is the market leader in the global ACE inhibitors market in 2018, with more than 70% market share. Zestril, Prinivil, and Qbrelis are some commonly used lisinopril brands available in the market.

  • Enalapril: Enalapril holds the second-highest market share in the global ACE inhibitors market. It is sold under brand names, including Vasotec, Epaned. According to the MRFR analysis, US sales for epanel oral solution in 2018 was close to USD 35 million.

  • Ramipril: Ramipril is a commonly used drug to treat hypertension. It comes in 1.25 mg, 2.5 mg, 5 mg, and 10 mg dosage.

  • Benazepril: Benazepril is marketed under the brand name of Lotensin. It is used to treat Heart Failure, Hypertension, and diabetic kidney disorders.

  • Fosinopril: It is used for the treatment of heart failure and hypertension. This is the only phosphinate-containing angiotensin-converting enzyme inhibitor manufactured by Bristol-Myers Squibb Company.

  • Captopril: This drug was patented in 1976, and its medical use was started in 1980. It is a market under brand names, including Capoten and Captopril.

  • Moexipril: Moexipril is used along with antihypertensives or diuretics to manage hypertension and congestive heart failure.

  • Others

By Application

  • Heart Failure: ACE inhibitors play an important role in the management of heart failure. It helps in relaxing blood vessels and reducing blood pressure to maintain uninterrupted blood flow. This segment holds significant market share in the global ACE inhibitors market owing to the rising cases of heart failure in developing countries. For instance, in 2018, more than 920,000 patients are suffering from heart failure in the UK.

  • Hypertension: Primary hypertension is the prevalent form of hypertension, affecting about 95% of hypertensive patients. Rising number of hypertension is likely to increase the demand for ACE Inhibitors.

  • Diabetes: Diabetes segment is expected to be the fastest-growing segment during the forecast period due to the rising cases of type 2 diabetes. According to a report published by the International Diabetes Federation, in 2017, more than 72.94 million patients were affected by diabetes.

  • Heart Attack

  • Chronic Kidney Disease

  • Others

By Dosage Form

  • Oral Tablets: The largest segment by dosage form, owing to the easy availability, cost-effectiveness, and flexibility.

  • Oral Solution: The fastest-growing segment due to the rising adoption of oral solutions in the treatment of hypertension and heart failure.

By Distribution Channel

  • Retail Pharmacy: It is the largest segment by distribution channel. Most drugs for hypertension are prescribed medications and easily available in retail pharmacies, and thus most of the patients prefer buying them from retail pharmacies.

  • Hospital Pharmacy: The market share of the segment is mainly attributed to the increasing number of patients treated with hypertension in hospitals, as they prefer to purchase drugs from hospital pharmacies.

  • E-commerce Websites and Online Drug Stores: The increasing adoption of internet facilities for purchasing drugs is expected to contribute to the market growth of the segment. It is likely to register the highest CAGR during the forecast period.

  • Others: Others include wholesalers or distributors for ACE inhibitors drugs

By Region

  • Americas: The Americas is estimated to dominate the global ACE inhibitors market. The Americas is further segmented into North America and South America. This region is expected to hold maximum market share in the global market, attributed to the rising prevalence of hypertension. Moreover, Cardiovascular disorders such as hypertension remains a significant public health challenge in the US due to the changing lifestyle. According to data published by the Centers for Disease Control and Prevention in October 2017, the prevalence of hypertension among adults in the US was 29.0% from 2015 to 2016.

  • Europe: The European market for ACE Inhibitors is expected to be the second-largest market. The risk of cardiovascular diseases is directly linked to both systolic and diastolic blood pressure levels. Physical inactivity, unhealthy diet, and obesity collectively increase the risk of raised blood pressure (hypertension).

  • Asia-Pacific: The fastest-growing regional market for ACE Inhibitors. Asia-Pacific has the world’s largest population and a fast-developing healthcare sector. Additionally, increasing cardiac diseases in countries like India and China are expected to drive the growth of the market.

  • Middle East & Africa: The Middle East and Africa is expected to witness steady growth due to limited access and healthcare affordability among the population. The local drug manufacturing companies in gulf regions represent a poor outlook in terms of drugs and depend mainly on imports.

Key Players

  • Bristol-Myers Squibb Company

  • Par Pharmaceutical Companies, Inc.

  • UCB, Inc.

  • Pfizer, Inc.

  • AbbVie Inc.

  • AstraZeneca

  • Bausch Health Companies, Inc.

  • Novartis AG

  • Merck & Co., Inc.

  • Teva Pharmaceutical Industries Ltd.

  • Silvergate Pharmaceuticals, Inc.

  • Others

Report Scope:
Report Attribute/Metric Details
  Market Size   USD 7682.8 Million
  CAGR   (3.10%) :2019-2025
  Base Year   2019
  Forecast Period   2025
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors and Trends
  Segments Covered   Drug, Application, Dosage Form, Distribution Channel and Region
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Bristol-Myers Squibb Company, Par Pharmaceutical Companies, Inc., UCB, Pfizer, AbbVie Inc., AstraZeneca Bausch Health Companies, Novartis AG, Merck & Co., Teva Pharmaceutical Industries Ltd., Silvergate Pharmaceuticals
  Key Market Opportunities

  • Innovative products
  • Changing lifestyle
  •   Key Market Drivers

  • Adoption of ACE Inhibitors in the management of chronic disorders
  • Increasing prevalence of hypertension and other cardiovascular disorders
  • Rising demand for less expensive drugs

  • Frequently Asked Questions (FAQ) :

    ACE Inhibitors Market is projected to grow at approximately 3.10% CAGR during the assessment period (2019-2025).

    ACE Inhibitors Market is estimated to reach a valuation of approx. USD 7682.8 MN by the end of 2025

    Rising adoption of ACE inhibitors for the treatment of cardiovascular complications and diabetic neuropathy, are major tailwinds pushing the growth of the global ACE inhibitors market.

    North America holds the largest share in the Global ACE Inhibitors Market, followed by Europe and the Asia Pacific, respectively.

    Par Pharmaceutical Companies, Inc. (US), Merck & Co., Inc.(US), Bristol-Myers Squibb Company (US), Teva Pharmaceutical Industries Ltd.(Israel), UCB, Inc. (Belgium), AstraZeneca (UK), AbbVie Inc.(US), Novartis AG (Switzerland), Pfizer, Inc.(US), Bausch Health Companies Inc.(Canada), and Silvergate Pharmaceuticals, Inc. (US), are some of the top players operating in the Global ACE Inhibitors Market.

    This table of content is tentative and subject to change as the research progresses.

    Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.